UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NATI
826
DELISTED
National Instruments Corp
NATI
| $13.2M | 0.01% |
+251,359
| New | +$12.6M |
|
827
nVent Electric
NVT
$26.7B
| $13.1M | 0.01% |
305,281
+10,457
| +4% | +$441K |
|
828
Denali Therapeutics
DNLI
$3.97B
| $13.1M | 0.01% |
567,141
+23,218
| +4% | +$639K |
|
829
Jefferies Financial Group
JEF
$13.1B
| $13M | 0.01% |
409,508
-9,118
| -2% | -$329K |
|
830
Prelude Therapeutics
PRLD
$390M
| $13M | 0.01% |
2,273,894
-62,050
| -3% | -$378K |
|
831
SITE Centers
SITC
$165M
| $12.9M | 0.01% |
1,348,310
+26,095
| +2% | +$265K |
|
832
Infosys
INFY
$50.7B
| $12.9M | 0.01% |
738,634
-26,800
| -4% | -$488K |
|
833
argenx
ARGX
$54.1B
| $12.8M | 0.01% |
34,479
-5,664
| -14% | -$2.1M |
|
834
Jones Lang LaSalle
JLL
$16.7B
| $12.8M | 0.01% |
87,923
+3,212
| +4% | +$535K |
|
835
MaxLinear
MXL
$6.8B
| $12.8M | 0.01% |
363,239
-2,590
| -0.7% | -$93.8K |
|
836
Halozyme
HALO
$12.2B
| $12.8M | 0.01% |
334,608
-183,871
| -35% | -$8.62M |
|
837
Coty
COTY
$2.48B
| $12.7M | 0.01% |
1,050,475
+38,163
| +4% | +$404K |
|
838
Ameresco
AMRC
$1.36B
| $12.6M | 0.01% |
+256,728
| New | +$13.6M |
|
839
Middleby
MIDD
$6.08B
| $12.6M | 0.01% |
86,188
+712
| +0.8% | +$106K |
|
840
Sunstone Hotel Investors
SHO
$2.06B
| $12.6M | 0.01% |
1,274,575
+81,690
| +7% | +$829K |
|
841
Axalta
AXTA
$8.17B
| $12.5M | 0.01% |
413,624
+14,848
| +4% | +$427K |
|
842
Primerica
PRI
$9.89B
| $12.5M | 0.01% |
72,643
+4,005
| +6% | +$656K |
|
|
DQ
843
Daqo New Energy
DQ
$996M
| $12.5M | 0.01% |
266,947
-12,511
| -4% | -$575K |
|
844
Douglas Emmett
DEI
$1.96B
| $12.4M | 0.01% |
1,009,306
+33,872
| +3% | +$492K |
|
845
Sabra Healthcare REIT
SBRA
$5.37B
| $12.4M | 0.01% |
1,081,807
+16,606
| +2% | +$205K |
|
846
PVH
PVH
$4.04B
| $12.4M | 0.01% |
138,704
+11,779
| +9% | +$961K |
|
|
ISEE
847
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $12.1M | 0.01% |
499,048
+379,651
| +318% | +$8.31M |
|
|
RCM
848
DELISTED
R1 RCM Inc. Common Stock
RCM
| $12.1M | 0.01% |
808,186
-5,800
| -0.7% | -$79.4K |
|
849
iShares MSCI Taiwan ETF
EWT
$11.1B
| $12.1M | 0.01% |
266,009
| – | – |
|
850
CACI
CACI
$14.2B
| $12M | 0.01% |
40,602
-2,047
| -5% | -$603K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.